ClinicalTrials.gg
RecruitingNCT06555575Updated Nov 3, 2026

Ubiquinone vs. Ubiquinol Supplementation

A Phase 2 interventional study of Ubiquinone 200 Mg Oral Capsule and Ubiquinol 100 MG Oral Capsule in IVF, sponsored by Trio Fertility. Recruiting at 1 site in Canada. Open to female participants aged 37 Years to 43 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Trio Fertility · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 9 months later.
Updated Nov 3, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
37 Years to 43 Years
Sex
Female
01

Study summary

The objective of this study is to determine if ubiquinol will result in improved reproductive outcomes in older women at a reduced oral dose compared to current standard treatment with ubiquinone.

Read the detailed description

As more women choose to delay child rearing, it has become increasingly important to understand why fertility declines with increasing maternal age. One of the factors suggested to play a role in reproductive aging is mitochondrial aging. Mitochondria are considered to be the batteries of the eggs and are responsible for generating energy necessary for egg and subsequent embryo development.

The egg maturation process involves a combination of many changes - all of which require energy that is provided by the mitochondria. Coenzyme Q10 (CoQ10) plays an important role as fuel in this process.

The investigators have shown that CoQ10 is needed for proper energy production by mitochondria and its addition to the diet could act as a potential treatment for egg aging.

It has been shown that in an aged mouse model, administration of CoQ10 (ubiquinone) results in improved mitochondrial energy production, more healthy embryos and more live-born pups. In clinical studies, the investigators also showed potential beneficial effects to increase the number of normal embryos from human eggs in older patients. So far, only one small study measured CoQ10 concentrations in the fluid that surrounds the eggs inside the ovaries (follicular fluid) and found significantly higher CoQ10 in the follicular fluid of normal mature eggs vs abnormal eggs. In addition, higher CoQ10 concentrations were also associated with better quality embryos. This study supports the hypothesis that CoQ10 supplementation may improve egg and embryo quality.

So far, all the research studies of CoQ10 in reproductive aging have administered a form of CoQ10 called ubiquinone. Another form of CoQ10 (ubiquinol), appears to be absorbed by the body better than ubiquinone and may have other beneficial effects in the ovary besides just increasing energy production.

02

Conditions studied

  • IVF

Keywords

  • ubiquinone
  • ubiquinol
  • reproductive outcome
03

In context

Lead sponsor

Trio Fertility is the lead sponsor of 5 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
37 Years to 43 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Women age >37 and \<43 years undergoing their first in vitro fertilization (IVF) cycle
  2. Day 3 follicle-stimulating hormone (FSH) \<12 IU/L with serum estradiol \<250 pmol/L and normal thyroid-stimulating hormone (TSH) and Prolactin
  3. Partner with semen analysis suitable for IVF or ICSI
  4. Anti-müllerian hormone (AMH) > 3 pmol/L
  5. Be willing and able to provide written for the study.
  6. Be an otherwise healthy female and considered eligible by the investigator to be treated with a daily dose of 225 IU Recombinant human FSH (recFSH) and 75 IU Human menopausal gonadotrophins (hMG).
  7. Documented history of infertility for at least 12 months before randomization (not applicable in case of tubal infertility or severe male factor infertility, or when the use of donor sperm is indicated)
  8. Have a (BMI) ≥17.5 and ≤38 kg/m2
  9. Have available ejaculatory sperm (use of donated and/or cryopreserved sperm is allowed)
  10. Have a normal uterine cavity (no evidence of uterine polyp or submucosal fibroid) as assessed by either saline-infused sonohysterography or by hysteroscopy within 12 months of randomization
  11. Have results of clinical laboratory tests (hematology, serum chemistry, and urinalysis) within normal limits or clinically acceptable to the investigator
  12. Has a pelvic ultrasound showing no cyst ≥15 mm

Exclusion criteria

Exclusion Criteria:

  1. Has been diagnosed with or treated for any endocrine abnormality within 3 years prior Note: Participants with a history of clinical or subclinical hypothyroidism may be eligible if thyroid stimulating hormone levels at screening are within normal limits and the participant has been on a stable dose of thyroid replacement medication (or on no replacement therapy) for at least 8 weeks.
  2. Has a prolactin level above the for the central laboratory
  3. Has FSH >12.0 IU/L
  4. Has a history of a full or partial resection of an ovary, including a history of ovarian cystectomy, or of any ovarian tumors limiting access to the ovary during ovum pick-up, e.g., endometriomas or teratomas measuring >10 mm
  5. Has unilateral or bilateral hydrosalpinx that communicates with the endometrial cavity on screening ultrasound or hysterosalpingography.
  6. Has intramural fibroids ≥3 cm or submucosal fibroids of any size
  7. Has Asherman's syndrome (untreated) or endometrial polyps that have not been resected
  8. Has any congenital uterine abnormality which is associated with a decreased chance of pregnancy
  9. Inadequate visualization of 1 or both ovaries
  10. One or both ovaries not accessible for oocyte retrieval
  11. Has a history of recurrent pregnancy losses (i.e., >3 pregnancy losses)
  12. Has a history or current evidence of (HIV) Note: Results obtained within 1 year prior to signing the form are considered valid.
  13. Has tumors of the ovary, breast, uterus, pituitary, or hypothalamus
  14. Has a history of epilepsy, thrombophilia, diabetes, untreated or inadequately treated subclinical hypothyroidism, cardiovascular, gastrointestinal, hepatic, renal, pulmonary, or auto-immune disease requiring treatment within the last 3 years
  15. Is a current smoker who smokes ≥5 cigarettes per day
  16. Is assessed by the Investigator as unlikely or unable to adhere to dose and/or visit schedules
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    coQ10 A

    Eligible subjects will be receiving ubiquinone 200 mg prior to their in vitro fertilization (IVF) cycle.

    Drug: Ubiquinone 200 Mg Oral Capsule

  • Experimental
    coQ10B

    Eligible subjects will be receiving ubiquinol 100 mg prior to their IVF cycle.

    Drug: Ubiquinol 100 MG Oral Capsule

  • No intervention
    Control

    Subjects are not receiving coQ10 supplementation.

Interventions

06

What researchers measure

Primary outcomes

  1. Fertilized oocyte percentage

    The primary outcome measure will be percentage of fertilized oocytes reaching the blastocyst stage (day 5 or 6 in culture)

    Time frame: Through study completion, an average of 1 year.

Secondary outcomes

  1. coQ10 level

    CoQ10 levels in plasma and follicular fluid

    Time frame: through study completion, an average of 1 year

  2. Protein structural change

    Rate of structural changes occurring in proteins of the follicular fluid and granulosa (GC) or cumulus (CC) cells representing oxidative stress

    Time frame: through study completion, an average of 1 year

  3. MII oocyte percentage

    Percentage of MII oocytes per total oocytes retrieved, normal 2PN fertilization rate

    Time frame: through study completion, an average of 1 year

  4. Reproductive outcome

    Number of day 3 embryos and ongoing pregnancy rate

    Time frame: through study completion, an average of 1 year

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Jan 2025 (actual). Primary completion is estimated for Sep 2027, 31 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 3, 2026: primary completion Sep 2026 → Sep 2027 and completion Jan 2027 → Sep 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2024
First posted
Aug 15, 2024
StartActual
Jan 23, 2025
Primary completionEst.
Sep 1, 2027was Sep 2026
CompletionEst.
Sep 2027was Jan 2027
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 1, 2026→Sep 1, 2027
Nov 3, 2026
Study completion
Jan 2027→Sep 2027
Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    Primary completion Sep 1, 2026→Sep 1, 2027
    Study completion Jan 2027→Sep 2027
    + 4 other changes: verification date, oversight details, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06555575
Lead sponsor
Trio Fertility
Responsible party
Sponsor
First posted
Aug 15, 2024
Start date
Jan 23, 2025
Primary completion
Sep 1, 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Nov 3, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Coenzyme Q10 · Ubiquinol

Start the discussion